AQR Capital Management - CTI BIOPHARMA CORP ownership

Quarter-by-quarter ownership
AQR Capital Management ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q4 2016$33,000
+10.0%
80,7000.0%0.00%
Q3 2016$30,000
+11.1%
80,7000.0%0.00%
Q2 2016$27,000
-37.2%
80,7000.0%0.00%
Q1 2016$43,000
-56.6%
80,7000.0%0.00%
Q4 2015$99,000
-16.1%
80,7000.0%0.00%
Q3 2015$118,000
-49.4%
80,700
-32.5%
0.00%
Q2 2015$233,000
+7.9%
119,6000.0%0.00%
Q1 2015$216,000
-23.4%
119,6000.0%0.00%
-100.0%
Q4 2014$282,000
-2.4%
119,6000.0%0.00%0.0%
Q3 2014$289,000
-14.0%
119,6000.0%0.00%0.0%
Q2 2014$336,000119,6000.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q3 2023
NameSharesValueWeighting ↓
BVF INC/IL 44,796,940$18,053,0003.63%
Stonepine Capital Management, LLC 2,617,136$1,067,0000.64%
FIRST NEW YORK SECURITIES LLC /NY 35,000$14,266,0000.03%
UNITED CAPITAL FINANCIAL ADVISORS, LLC 526,210$2,157,0000.02%
Caprock Group, LLC 150,000$61,0000.02%
TIEDEMANN ADVISORS, LLC 334,310$136,0000.01%
JW Asset Management, LLC 50,254$21,0000.01%
Nine Chapters Capital Management LLC 17,200$7,0000.01%
TWO SIGMA SECURITIES, LLC 60,419$24,0000.01%
WASHINGTON TRUST Co 314,000$128,0000.01%
View complete list of CTI BIOPHARMA CORP shareholders